Mark Adamchak's most recent trade in Bionano Genomics Inc was a trade of 3 Common Stock done at an average price of $1 . Disclosure was reported to the exchange on Feb. 17, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bionano Genomics Inc | Mark Adamchak | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.00 per share. | 17 Feb 2026 | 3 | 260 (0%) | 0% | 1 | 3 | Common Stock |
| Bionano Genomics Inc | Mark Adamchak | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 10,890 | 10,890 | - | - | Stock Option (Right to Buy) | |
| Bionano Genomics Inc | Mark Adamchak | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.71 per share. | 03 Jun 2025 | 7 | 263 (0%) | 0% | 3.7 | 26 | Common Stock |
| Bionano Genomics Inc | Mark Adamchak | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 3,029 | 3,029 | - | - | Stock Option (Right to Buy) | |
| Bionano Genomics Inc | Mark Adamchak | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.75 per share. | 15 Feb 2025 | 4 | 270 (0%) | 0% | 5.8 | 23 | Common Stock |
| Bionano Genomics Inc | Mark Adamchak | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) |